<DOC>
	<DOCNO>NCT02968836</DOCNO>
	<brief_summary>Assessment Safety efficacy amino acid blend muscle gut functionality Intensive Care Unit ( ICU ) patient .</brief_summary>
	<brief_title>Safety Efficacy Amino Acid Blend Muscle Gut Functionality ICU Patients</brief_title>
	<detailed_description>This monocentric trial parallel , randomize , double-blind , control study . Patients hospitalize ICU sepsis enrol . The treatment group ( n=15 ) administer study product ( amino acid blend ) negative control group ( =15 ) administrate maltodextrin . The mode administration nasogastric probe . The treatment period 21 day . Subject follow stay High care intermediate care unit 2 month hospital discharge follow 12 month . Recruitment stop 30 patient ( 15 group ) reach V4 .</detailed_description>
	<criteria>1 . Patients age 18 2 . Sepsis patient : expect stay least 21 day ICU ( midcare ) , opinion investigator 3 . Documented infection Sequential Organ Failure Assessment ( SOFA ) score 2 point 4 . Informed consent sign patient or/and his/her representative 1 . Patient muscle mass loss due previous hospitalization 2 . Intolerance enteral feed 3 . Patients use parenteral feed 4 . Chronic renal failure opinion investigator 5 . Chronic liver disease opinion investigator 6 . Chronic intestinal disease ( Inflammatory Bowel disease IBD , Crohn 's , ulcerative colitis ) 7 . Current treatment chemotherapy radiotherapy cancer 8 . Cachectic patient 9 . Current treatment paralyze drug 10 . No pacemaker metal implant interact MRI magnetic stimulation 11 . Pregnant woman ( know ) 12 . Persons without social security 13 . Under guardianship 14 . Currently participate participate another clinical trial within 4 week prior trial start 15 . Patient expect comply study procedure , opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>